The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2

Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),is the currently recommended first-line therapy for advanced EGFR-mutant lung cancer, and understanding the mechanism of resistance is the key to formulating therapeutic strategies for EGFR-TKIs. In this study, we ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Shengnan, Zhu, Ya, Wang, Siying, Zhang, Qinqiu, Zhang, Niu, Zou, Xiaoteng, Wei, Chenchen, Wang, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157544/
https://www.ncbi.nlm.nih.gov/pubmed/36471952
http://dx.doi.org/10.3724/abbs.2022176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157544/
https://www.ncbi.nlm.nih.gov/pubmed/36471952
http://dx.doi.org/10.3724/abbs.2022176

Ejemplares similares